Zymar

Zymar is a brand name of gatifloxacin ophthalmic, approved by the FDA in the following formulation(s):

ZYMAR (gatifloxacin - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: March 28, 2003
  
  Strength(s): 0.3% ^[RLD][AT]

Has a generic version of Zymar been approved?

A generic version of Zymar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zymar and have been approved by the FDA:

gatifloxacin solution/drops; ophthalmic

• 
  Manufacturer: APOTEX CORP
  
  Approval date: August 19, 2011
  
  Strength(s): 0.3% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zymar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
  Patent 5,880,283
  Issued: March 9, 1999
  Inventor(s): Matsumoto; Toyomi & Hara; Masamoto & Miyashita; Kunio & Kato; Yukihiro
  Assignee(s): Kyorin Pharmaceutical Co., Ltd.
  The invention provides 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid sesquihydrate with excellent stability represented by a following formula (1), ##STR1## and process for producing the same.
  
  Patent expiration dates:
  
  
  • December 5, 2015
    
  
  
  
  • June 5, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Aqueous liquid pharmaceutical composition comprised of gatifloxacin
  Patent 6,333,045
  Issued: December 25, 2001
  Inventor(s): Yasueda; Shinichi & Inada; Katsuhiro
  Assignee(s): Senju Pharmaceutical Co., Ltd.
  Kyorin Pharmaceutical Co., Ltd.
  There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
  
  Patent expiration dates:
  
  
  • August 20, 2019
    
    ✓ 
    Drug product
  
  
  
  • February 20, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zymar Drops Consumer Information (Wolters Kluwer)
• Zymar Consumer Information (Cerner Multum)
• Zymar Advanced Consumer Information (Micromedex)
• Zymar eent AHFS DI Monographs (ASHP)
• Gatifloxacin Drops Consumer Information (Wolters Kluwer)
• Gatifloxacin ophthalmic Consumer Information (Cerner Multum)
• Gatifloxacin Ophthalmic Advanced Consumer Information (Micromedex)
• Gatifloxacin eent AHFS DI Monographs (ASHP)